Vasant Narasimhan

“When you look at what underpins R&D in our industry, it's been primarily in the United States,”

“In 2025, we were able to navigate a lot of the geopolitical complexities for Novartis. I think the industry overall, on US tariffs, has good solutions. With the MFN agreements, we now have certainty on how we're going to approach drug pricing in the US, which I think is a de-risking event for the industry. This year will be much more focused, at least for us, on innovation, new launches, and getting more medicines out. So I'm actually quite excited about the year. For Novartis, we do have to nav”

“The healthcare debate in the U.S. needs to shift away from list prices and net prices toward a focus on reducing patient out-of-pocket costs.”

“If Europe wants to attract investment like the US and China right now, it has to step up,”

“Swiss pharmaceutical giant Novartis' CEO has said he "thinks" the company has an agreement with the U.S. to shield it from tariffs.”